| Field | Specification |
|---|---|
| Target | |
| Alternative names | Aldo-keto reductase family 1 member C2;1.-.-.-;3-alpha-HSD3;Chlordecone reductase homolog HAKRD;Dihydrodiol dehydrogenase 2;DD-2;DD2;Dihydrodiol dehydrogenase/bile acid-binding protein;DD/BABP;Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase;1.3.1.20 ;Type III 3-alpha-hydroxysteroid dehydrogenase;1.1.1.357 ;AKR1C2;DDH2; |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human AKR1C1/C2 recombinant protein (Position: M1-K123). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets aldo-keto reductase family 1 member C2 (gene AKR1C2) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF and Western blot. The predicted molecular weight is 36.7 kDa, and the supplier reports an observed band at about 37 kDa.
AKR1C2 is a cytosolic aldo-keto reductase that reduces ketosteroids to hydroxysteroids using NADPH, acting mainly as a 3α-hydroxysteroid dehydrogenase. It inactivates dihydrotestosterone, forms neurosteroids such as allopregnanolone, and takes part in the alternative (backdoor) route of androgen synthesis.
| Target | Aldo-keto reductase family 1 member C2 (gene AKR1C2; UniProt P52895, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 36.7 kDa |
| Observed MW | 37 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HepG2 cells, human A549 cells, human hccp tissue, rat liver tissue, rat kidney tissue, mosue liver tissue, mosue kidney tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (ICC/IF): HepG2 cells.
Samples with a confirmed signal (flow cytometry): HepG2 cells.
Immunogen
Recombinant human AKR1C1/C2 fragment (Met1–Lys123), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places aldo-keto reductase family 1 member C2 in the cytoplasm. Tissue expression noted by UniProt (human): Expressed in fetal testes. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Gao Yunshu et al. (2021) Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling. Frontiers in Oncology. 10.3389/fonc.2021.677678
